Diplomat Pharmacy (NYSE:DPLO) fell 10% today following the report of its third-quarter earnings after the bell yesterday, although the results didn't look too bad.
Sure, revenue of $1.1 billion was down slightly from the $1.2 billion in the year-ago quarter. But gross margins were 7.6%, up 1000 basis points from 6.6% in the year-ago quarter.
Earnings per share (EPS) on a GAAP basis fell from $0.08 in the year-ago quarter to $0.01 in the most recent quarter. But when you subtract out one-time items, adjusted earnings were $0.25 per share, up from $0.21 per share last year.
Management raised the bottom end of its 2017 revenue guidance, which it now expects will fall between $4.4 billion and $4.6 billion. Adjusted earnings per share were raised substantially to between $0.82 and $0.87 compared to a previous range of $0.71 and $0.79.
This is a transition year for Diplomat Pharmacy as it diversifies its offerings to the drug companies it supplies medications for and expands its specialty infusion business. Considering that the stock is up almost 50% this year even after the drop, today's move may have more to do with investors taking profits than a reaction to the third quarter.